Dr. Bussel studies the effect of TNF blockers on regulatory T cells. TNF blockers may be effective in treating ITP patients through its ability to promote regulatory T cell production. Published in British Journal of Haematology on September 2014.

Dr. Bussel studies the effect of rituximab and 3 dexamethasone cycles as a possible medical cure for ITP patients. Women and patients that were treated within two years of diagnosis responded especially well to treatment. Published in Haematologica on April 2014.

Dr. Mitchell was part of a reserach team that studied the mechanism of Rho kinase inhibition which promotes platelet production. Thei findings advance our knowledge of control mechanisms during the later stages of megakaryocyte maturation and platelet formation, which may help point to new strategies in developing ex vivo platelet culture systems. Published in Journal of Haematology on January 2014.

Dr. Bussel and his team conducted a randomized, double blind study of romiplostim to to determine its safety and efficacy in children with ITP. Learn more by reading this publication which was featured in Blood Journal. 

Dr. Bussel's study which examines and compares platelet function in severely thrombocytopenic patients with acute myeloid leukaemia (AML) or myelodysplasia (MDS) to patients with immunte thrombocytopenia (ITP). 

Dr. Bussel recently published an artible in the March 2010 issue of The Hematologist about changes in approaching ITP over the past few years.